Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.546 million which beat the analyst consensus estimate of $1.200 million by 28.83 percent.